iBio, Inc. IBIO
NASDAQ IBIO
$0.82 +0.04 (+5.67%)
At close: Nov 11, 2026 · 4:00 PM EST

iBio (IBIO) Construction in Progress (2021 - 2022)

Updated

Analysis

iBio (IBIO) Construction in Progress (2021 - 2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 iBio 118.23 Mn -174.02 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2022 82,000.00
Dec 31, 2021 82,000.00
Sep 30, 2021 82,000.00
API Access

iBio Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=IBIO&period=max&api_key=YOUR_API_KEY